HK1070821A1 - Extended release venlafaxine tablet formulation - Google Patents

Extended release venlafaxine tablet formulation

Info

Publication number
HK1070821A1
HK1070821A1 HK05103497A HK05103497A HK1070821A1 HK 1070821 A1 HK1070821 A1 HK 1070821A1 HK 05103497 A HK05103497 A HK 05103497A HK 05103497 A HK05103497 A HK 05103497A HK 1070821 A1 HK1070821 A1 HK 1070821A1
Authority
HK
Hong Kong
Prior art keywords
core
filler
cellulosic polymer
extended release
microcrystalline cellulose
Prior art date
Application number
HK05103497A
Other languages
English (en)
Inventor
Sima Volpert
Original Assignee
Dexcel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32981939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1070821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dexcel Ltd filed Critical Dexcel Ltd
Publication of HK1070821A1 publication Critical patent/HK1070821A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK05103497A 2003-05-02 2005-04-23 Extended release venlafaxine tablet formulation HK1070821A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03101216.4A EP1473030B2 (en) 2003-05-02 2003-05-02 Extended release Venlafaxine tablet formulation

Publications (1)

Publication Number Publication Date
HK1070821A1 true HK1070821A1 (en) 2005-06-30

Family

ID=32981939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103497A HK1070821A1 (en) 2003-05-02 2005-04-23 Extended release venlafaxine tablet formulation

Country Status (9)

Country Link
US (1) US8105627B2 (es)
EP (1) EP1473030B2 (es)
AT (1) ATE344659T1 (es)
CA (1) CA2524241A1 (es)
DE (1) DE60309565T3 (es)
ES (1) ES2277030T3 (es)
HK (1) HK1070821A1 (es)
PT (1) PT1473030E (es)
WO (1) WO2004096186A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105627B2 (en) 2003-05-02 2012-01-31 Dexcel Ltd. Extended release venlafaxine tablet formulation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
WO2006136927A1 (en) * 2005-06-22 2006-12-28 Glenmark Pharmaceuticals Limited Extended release formulations comprising venlafaxine
US20070014859A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
EP2074993A1 (en) * 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxine-containing film-coated modified-release tablets
US20110052690A1 (en) * 2008-06-02 2011-03-03 Avi Avramoff Process for manufacture of a medicament with granulation and pan coating
WO2010089775A2 (en) * 2009-02-05 2010-08-12 Getz Pharma Research Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent
AU2011251747B2 (en) * 2010-05-14 2014-08-07 Alembic Limited Extended release formulations of desvenlafaxine base
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4657757A (en) † 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) † 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001037815A1 (en) * 1999-11-22 2001-05-31 Alza Corporation Osmotic dosage form comprising first and second
US6350471B1 (en) † 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
DE60309565T3 (de) 2003-05-02 2015-01-15 Dexcel Ltd. Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
EP1523981A1 (en) † 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105627B2 (en) 2003-05-02 2012-01-31 Dexcel Ltd. Extended release venlafaxine tablet formulation

Also Published As

Publication number Publication date
DE60309565T3 (de) 2015-01-15
AU2003285739A1 (en) 2004-11-23
PT1473030E (pt) 2007-01-31
ES2277030T3 (es) 2007-07-01
EP1473030A1 (en) 2004-11-03
WO2004096186A1 (en) 2004-11-11
US8105627B2 (en) 2012-01-31
EP1473030B1 (en) 2006-11-08
CA2524241A1 (en) 2004-11-11
ATE344659T1 (de) 2006-11-15
DE60309565D1 (de) 2006-12-21
EP1473030B2 (en) 2014-05-14
DE60309565T2 (de) 2007-03-15
US20070082049A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
HK1070821A1 (en) Extended release venlafaxine tablet formulation
AU686168B2 (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
BG66095B1 (bg) Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
CA2392013A1 (en) Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene
WO2010049433A3 (en) Water insoluble polymer: starch-based film coatings for colon targeting
HUP0002744A2 (hu) Gyors hatóanyag-leadású és ízmaszkírozó gyógyászati dózisforma
TW200640501A (en) Crush resistant delayed-release dosage forms
WO2006096194A3 (en) Drinkable immediate release tablet made with direct compression of memantine or neramexane
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
PL181215B1 (pl) Kompozycja farmaceutyczna zawierająca ibuprofen i kodeinę oraz sposób jej wytwarzania
WO2007132293A3 (en) Once-daily administration of central nervous system drugs
PL379465A1 (pl) Preparat o przedłużonym uwalnianiu dla chlorowodorku wenlafaksyny
RS20060252A (en) Pelletes containing venlafaxine hydrochloride
MXPA05004412A (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas.
WO2006081779A3 (en) A pharmaceutical composition containing olanzapine as the active agent and a process for the preparation thereof
CA2421240A1 (en) Granular preparations for oral administration
TW200621314A (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2006017787A3 (en) Tablet coating composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120502